Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Sarcoma
NCT03491371Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Rivoceranib in osteosarcoma (OS), Ewing sarcoma, chondrosarcoma and 1 more (4 arms), sponsored by Peking University People's Hospital. Primary endpoint: Objective Response Rate at 3 months. Started Jun 2015; status: completed.
02
Drugs
Rivoceranib
03
Conditions
osteosarcoma (OS)Ewing sarcomachondrosarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03491371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491371.